Friday 5-16-2014 Galena Biopharma (GALE) $GALE ope
Post# of 88
Posted On: 05/17/2014 12:53:24 PM
Friday 5-16-2014 Galena Biopharma (GALE) $GALE opened at 2.21 hitting the high price of 2.25 and a day low of 2.12 with a total volume of 1,211,700. GALE had a previous close of 2.22 and has been seeing an average volume of 3,506,985.
Overall Average: 72% Sell
Recent stock forum discussions about GALE http://investorshangout.com/search?q=GALE&...mp;yt0=Go!
SEC Casting Wide Net in Galena Investigation
at The Street - Wed May 14, 2:35PM CDT
Lion Bio received an SEC subpoena related to the Galena DreamTeam investigation. (full story)
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
Why Galena Biopharma Inc. Shares Surged Higher
Sean Williams, The Motley Fool - Motley Fool - Wed May 07, 1:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Galena Biopharma , a biopharmaceutical... (full story)
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria (full story)
Abstral Growth and a Warrant Valuation Benefit Shrink Galena's Q1 Loss by 73%
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 4:47PM CDT
Highly volatile and controversial small-cap biopharmaceutical Galena Biopharma gave optimists a reason to cheer after the closing bell this evening by delivering top- and bottom-line improvements with the release of its first-quarter results . ... (full story)
Galena Biopharma Reports First Quarter 2014 Results
GlobeNewswire - Tue May 06, 3:35PM CDT
-- Abstral net revenue was $2.2 million in Q1 2014, with full year guidance of $11 to $15 million for 2014. (full story)
GALENA BIOPHARMA, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against GALENA BIOPHARMA, INC. and Its Board and a Lead Plaintiff Deadline of May 5, 2014
Business Wire - Thu May 01, 12:35PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. ("Galena" or the "Company"
(Nasdaq:GALE) securities between November 6, 2013 and February 14, 2014. (full story)
Galena Biopharma to Present at the 39th Annual Deutsche Bank Health Care Conference
GlobeNewswire - Wed Apr 30, 6:16AM CDT
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the 39th Annual Deutsche Bank Health Care Conference. The presentation will take place on Wednesday, May 7, 2014 at 10:40 a.m. ET at The InterContinental Hotel in Boston, MA. (full story)
Why Galena Biopharma Inc. Shares Briefly Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 28, 12:58PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Galena Biopharma , a clinical-stage... (full story)
Galena Biopharma Announces Department of Defense Grant for NeuVax(TM) (nelipepimut-S) Clinical Trial
GlobeNewswire - Mon Apr 28, 6:13AM CDT
-- Phase 2 study in neoadjuvant, HER2 3+ Breast Cancer Patients to commence in 2014 (full story)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Galena Biopharma, Inc. of Class Action Lawsuit and Upcoming Deadline --- GALE
GlobeNewswire - Mon Apr 28, 4:27AM CDT
Pomerantz LLP has filed a class action lawsuit against Galena Biopharma, Inc. ("Galena" or the "Company" (Nasdaq:GALE) and certain of its officers. The class action, filed in United States District Court, District of Oregon, and docketed under 3:14-cv-00410-HZ, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Galena securities between March 12, 2013 and February 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. (full story)
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 26, 6:30AM CDT
Ho-hum? That might be the reaction of most to the overall market these days. You can bet that shareholders of these three health-care stocks aren't yawning, though. Each of them soared at least 27% this week. One stock leaped on a stunning reversal... (full story)
Overall Average: 72% Sell
Recent stock forum discussions about GALE http://investorshangout.com/search?q=GALE&...mp;yt0=Go!
SEC Casting Wide Net in Galena Investigation
at The Street - Wed May 14, 2:35PM CDT
Lion Bio received an SEC subpoena related to the Galena DreamTeam investigation. (full story)
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
Why Galena Biopharma Inc. Shares Surged Higher
Sean Williams, The Motley Fool - Motley Fool - Wed May 07, 1:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Galena Biopharma , a biopharmaceutical... (full story)
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria (full story)
Abstral Growth and a Warrant Valuation Benefit Shrink Galena's Q1 Loss by 73%
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 4:47PM CDT
Highly volatile and controversial small-cap biopharmaceutical Galena Biopharma gave optimists a reason to cheer after the closing bell this evening by delivering top- and bottom-line improvements with the release of its first-quarter results . ... (full story)
Galena Biopharma Reports First Quarter 2014 Results
GlobeNewswire - Tue May 06, 3:35PM CDT
-- Abstral net revenue was $2.2 million in Q1 2014, with full year guidance of $11 to $15 million for 2014. (full story)
GALENA BIOPHARMA, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against GALENA BIOPHARMA, INC. and Its Board and a Lead Plaintiff Deadline of May 5, 2014
Business Wire - Thu May 01, 12:35PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. ("Galena" or the "Company"
(Nasdaq:GALE) securities between November 6, 2013 and February 14, 2014. (full story) Galena Biopharma to Present at the 39th Annual Deutsche Bank Health Care Conference
GlobeNewswire - Wed Apr 30, 6:16AM CDT
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the 39th Annual Deutsche Bank Health Care Conference. The presentation will take place on Wednesday, May 7, 2014 at 10:40 a.m. ET at The InterContinental Hotel in Boston, MA. (full story)
Why Galena Biopharma Inc. Shares Briefly Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 28, 12:58PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Galena Biopharma , a clinical-stage... (full story)
Galena Biopharma Announces Department of Defense Grant for NeuVax(TM) (nelipepimut-S) Clinical Trial
GlobeNewswire - Mon Apr 28, 6:13AM CDT
-- Phase 2 study in neoadjuvant, HER2 3+ Breast Cancer Patients to commence in 2014 (full story)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Galena Biopharma, Inc. of Class Action Lawsuit and Upcoming Deadline --- GALE
GlobeNewswire - Mon Apr 28, 4:27AM CDT
Pomerantz LLP has filed a class action lawsuit against Galena Biopharma, Inc. ("Galena" or the "Company"
(Nasdaq:GALE) and certain of its officers. The class action, filed in United States District Court, District of Oregon, and docketed under 3:14-cv-00410-HZ, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Galena securities between March 12, 2013 and February 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. (full story) 3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 26, 6:30AM CDT
Ho-hum? That might be the reaction of most to the overall market these days. You can bet that shareholders of these three health-care stocks aren't yawning, though. Each of them soared at least 27% this week. One stock leaped on a stunning reversal... (full story)
(0)
(0)